ECDC is monitoring reports from three countries (France, the United Kingdom and the United States) of cases of invasive meningococcal disease (IMD) associated with travel to the Kingdom of Saudi Arabia (KSA).
European Immunization Week (EIW) is marked across Europe every year in the final week of April. It aims to raise awareness of the importance of immunisation for the general health and well-being of the European and wider population.
In connection with the European Immunization Week, ECDC releases data indicating an increase in cases of vaccine-preventable diseases such as measles and pertussis, after decreased levels during the COVID-19 pandemic.
Since late February 2023 and up until 30 March 2023, 87 cases of botulism linked to intragastric injection of the botulinum neurotoxin (BoNT) have been reported.
Since late February 2023 and as of 10 March 2023, 67 cases of botulism linked to intragastric injection of the botulism neurotoxin (BoNT) have been reported in Germany (12), Austria (1), Switzerland (1) and Türkiye (53).
Immediate health needs following earthquakes in Türkiye and Syria are mostly related to trauma and the disruption of healthcare, however, infectious disease threats may be concerning in the following two to four weeks.
On 20 December 2016, ECDC and EFSA published a joint rapid outbreak assessment describing a cluster of six laboratory-confirmed German and Spanish cases of foodborne botulism caused by botulinum neurotoxin type E which occurred during November and December 2016. All of the six patients had consumed dried and salted roach, a fresh and brackish water fish (Rutilus rutilus).
On the occasion of the tenth anniversary of European Immunization Week, ECDC is releasing a new complement of data, tools, blogs and updates to support public health authorities in their work against vaccine preventable diseases.
Findings in this study confirmed the herd immunity effect of immunizing young children, since invasive meningococcal disease was not only reduced among vaccinees, but in all age groups.
4CMenB has the potential to reduce serogroup B meningococcal disease substantially. Despite its potential, the vaccine may have some limitations, and it remains to be seen if booster doses will be required to sustain protection.